Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Automate Your Wheel Strategy on CRBP
With Tiblio's Option Bot, you can configure your own wheel strategy including CRBP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CRBP
- Rev/Share 0.0
- Book/Share 10.4167
- PB 0.7699
- Debt/Equity 0.0225
- CurrentRatio 11.821
- ROIC -0.453
- MktCap 98139136.0
- FreeCF/Share -4.118
- PFCF -1.9531
- PE -1.946
- Debt/Assets 0.0204
- DivYield 0
- ROE -0.3687
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CRBP | William Blair | -- | Outperform | -- | -- | Feb. 28, 2025 |
News
Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data?
Published: June 17, 2025 by: Seeking Alpha
Sentiment: Neutral
CRBP's pipeline shows promise, especially CRB-701 with early signals of benefit and tolerability, but all programs remain in early clinical stages. The company's financial position is stable for now, with about two years of cash runway, but rising R&D costs could accelerate the need for funding. Market sentiment has become overly negative, valuing the pipeline at essentially zero after a steep drop unrelated to CRBP's own data.
Read More
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.
Read More
Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NORWOOD, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference, to be held June 3-5, 2025 in New York, NY.
Read More
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15.
Read More
Is Small-Cap Corbus Pharma a Worthy Cannabis Investment?
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
While CRBP's pipeline shows promise, the company's lack of marketed products remains a concern.
Read More
3 Unconventional Cannabis Stocks to Watch in 2025
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Think cannabis investing is all hype? These three unconventional stocks could change your mind - and your portfolio - in 2025.
Read More
Wall Street Analysts See a 764.18% Upside in Corbus Pharmaceuticals (CRBP): Can the Stock Really Move This High?
Published: April 18, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 764.2% in Corbus Pharmaceuticals (CRBP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
After Plunging -22.69% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)
Published: March 20, 2025 by: Zacks Investment Research
Sentiment: Negative
Corbus Pharmaceuticals (CRBP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Read More
Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's What You Should Know
Published: March 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025
Published: February 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
NORWOOD, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) (“Corbus” or the “Company”), announced that data from its US and UK conducted first-in-human dose escalation clinical study (“Western study”) of CRB-701 (SYS6002) is being presented today at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).
Read More
About Corbus Pharmaceuticals Holdings, Inc. (CRBP)
- IPO Date 2014-10-27
- Website https://www.corbuspharma.com
- Industry Biotechnology
- CEO Yuval Cohen
- Employees 28